回复@生意模式20年: ISR从拿到FDA，到真正临床应用还是有过程的，这个过程就是涉及到具体某个癌症种类的治疗许可、器具许可、国家许可等，这也是之前多年不涨的主要原因，这两年这个过程在加速，量变要到质变了：

January 29, 2014 ----- IsoRay Announces Greek Governmental Approval for Sales of It's Entire Product Line

October 14, 2013-----IsoRay's Cancer Fighting Cesium-131 Seeds, Sutures and Seeded Mesh Receive High Remarks with Six Abstracts Presented During (ASTRO) the American Society for Radiation Oncology Conference -

 June 25, 2013----Isoray Announces a New International Distributor in Australia and New Zealand

November 3, 2011：IsoRay, Inc. (Amex: ISR) announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite® radiation therapy system, a balloon catheter device used in the treatment of brain cancer.//@生意模式20年:回复@ISRFANS:周末2天向几个美国医院的朋友咨询了ISR，感觉其产品确实很吸引人，所以今天开盘就买入了$ISORAY INC(ISR)$